Valeant

Showing 15 posts of 90 posts found.

valeant_web

FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns

June 19, 2018
Manufacturing and Production, Sales and Marketing FDA, Valeant, pharma, psoriasis

Beleaguered pharma firm Valeant has come up against another bump in the road as its plaque psoriasis lotion Duobrii (halobetasol …

valeant_web

Valeant seeks clean slate with rebrand, new company name

May 9, 2018
Medical Communications, Research and Development Valeant, pharma

In the latest attempt to reverse its ailing fortunes and distance itself from its polluted brand, Canadian pharma firm Valeant …

shutterstock_92671375

Impax agrees to $35 million settlement over anticompetitive practices with Valeant generic

March 12, 2018
Sales and Marketing Impax, Medicis, Solodyn, Valeant, generic, pharma

Impax Pharmaceuticals has acquiesced to paying a $35 million settlement in order to resolve part of an antitrust lawsuit it …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten

Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …

valeant

Valeant and Pershing take $290m hit over insider trading

January 2, 2018
Manufacturing and Production, Sales and Marketing Bill Ackman, Pershing Square, Valeant, biotech, drugs, pharma, pharmaceutical

Valeant Pharmaceuticals will be hoping it can begin 2018 as a fresh start, after a turbulent few years, to say …

addyi-prescription

Valeant backs away from female libido pill

November 7, 2017
Manufacturing and Production, Sales and Marketing Addyi, Valeant, biotech, drugs, pharma, pharmaceutical

Only two years ago, Valeant was so keen to get involved with a pill reported to increase the female libido …

eye_2

Valeant begins long comeback trail with FDA approval

November 6, 2017
Sales and Marketing Valeant, Vyzulta, biotech, drugs, pharma, pharmaceutical

Valeant has had precious little to be happy about over the last few years, it’s bounced from one piece of …

valeant

Valeant focused on bringing new products to market, receives CRL

August 9, 2017
Research and Development, Sales and Marketing Valeant, biotech, drugs, pharma, pharmaceutical

In its second quarter financial reports, Valeant strove to strike a positive note. It revealed that it had paid down …

valeant

Valeant takes huge loss on previous deal to pay down debts

July 18, 2017
Manufacturing and Production, Sales and Marketing Obagi Medical Products, Valeant, biotech, drugs, pharma, pharmaceutical

It is an odd time for Valeant, where selling a part of its business for half of what it paid, …

shutterstock_138095450

New data shows pharma has not cut back on controversial payments to physicians

July 6, 2017
Medical Communications, Sales and Marketing Allergan, Biogen, Celgene, Sanofi, Valeant

Despite increasing controversy arising over the years due to the questionable relationship between physicians and pharma and the money which …

lavalbldg1806696_853705

Psoriasis drug Siliq will be cheapest in class, Valeant reveals

April 24, 2017
Sales and Marketing Siliq, Valeant, psoriasis

Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a …

valeant_web

Former Valeant CEO Michael Pearson sues over $30m unpaid shares

March 28, 2017
Manufacturing and Production, Sales and Marketing Michael Pearson, Valeant

Ex-Valeant CEO Michael Pearson is suing his former company over its failure to deliver three million shares he claims he …

lavalbldg1806696_853705

FDA approves Valeant plaque psoriasis drug despite suicide concerns

February 16, 2017
Sales and Marketing FDA, Siliq, Valeant, psoriasis

The US Food and Drug Administration (FDA) has announced that it has approved Valeant Pharmaceutical’s injectable psoriasis treatment Siliq (brodalumab) …

valeant_web

Valeant to sell cancer business to Sanpower for $820m

January 10, 2017
Manufacturing and Production, Sales and Marketing Dendreon, Sanpower, Valeant

Valeant Pharmaceuticals has announced it is to sell its cancer business Dendreon to Chinese firm Sanpower in a deal worth …

Latest content